The EU's competition commissioner issued the final report from investigating the delays in generic drugs coming to the market, reports the Wall Street Journal's Health Blog. The report acknowledged that innovation difficulties and regulation affect the time it takes to get a generic to market and suggested that the EU have a single patent and litigation system. However, the report also calls for keeping a sharper eye on pharmaceutical companies, "particularly the practice known as 'pay for delay', where generic makers strike a deal with branded companies to delay entry of generic competition into the marketplace," the Health Blog says, adding that separate antitrust investigations have begun into generics makers Les Laboratoires Servier and Teva.
'Pay for Delay'
Jul 09, 2009